NIMENRIX (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Dosage And Administration

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

Dosing Considerations

NIMENRIX should be used in accordance with available official recommendations.

Recommended Dose and Dosage Adjustment

*
See CLINICAL TRIALS – Immunogenicity in infants for further information.
**
In some situations, consideration may be given to administering an additional primary dose or a booster dose of NIMENRIX (see WARNINGS AND PRECAUTIONS – Protection Against Meningococcal Disease and CLINICAL TRIALS for further information).
Age GroupPrimary ImmunizationBooster
Infants from 6 weeks to less than 6 months of age*

Two doses, each of 0.5 mL, with the first dose given from 6 weeks of age, and with an interval of 2 months between doses

At 12 months of age
Unvaccinated infants from 6 months to less than 12 months of age**One dose of 0.5 mL given from 6 months of ageAt 12 months of age with a minimum interval of at least 2 months after the primary dose
Children from 12 months of age, adolescents and adults**One dose of 0.5 mLNot routinely administered 

 

NIMENRIX may be given as a booster dose to individuals who have previously received primary vaccination with NIMENRIX or other conjugated or plain polysaccharide meningococcal vaccines (see WARNINGS AND PRECAUTIONS – Protection Against Meningococcal Disease: Persistence of serum bactericidal antibody titres and CLINICAL TRIALS.

Administration

NIMENRIX is for intramuscular injection only.

In infants, the recommended injection site is the anterolateral aspect of the thigh. 

In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or deltoid muscle (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

For instructions on reconstitution of the vaccine before administration, see SPECIAL HANDLING INSTRUCTIONS.

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.